| Effect of systemic medications on onset and progression of diabetic retinopathy. | |
| | |
MedLine Citation:
|
PMID: 20664533 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Diabetic retinopathy remains a leading cause of visual loss worldwide. Patients with diabetes mellitus commonly have multiple comorbidities treated with a wide variety of medications. Systemic medications that target glycemic control and coexisting conditions may have beneficial or deleterious effects on the onset or progression of diabetic retinopathy. In addition, data is accumulating to suggest that the use of systemic therapy primarily to address ocular complications of diabetic retinopathy may be a promising therapeutic approach. This article reviews our current understanding of the ocular-specific effects of systemic medications commonly used by patients with diabetes mellitus, including those directed at control of hyperglycemia, dyslipidemia, hypertension, cardiac disease, anemia, inflammation and cancer. Current clinical evidence is strongest for the use of angiotensin-converting enzyme inhibitors and angiotensin-2 receptor blockers in preventing the onset or slowing the progression of early diabetic retinopathy. To a more limited extent, evidence of a benefit of fibrates for diabetic macular edema exists. Numerous other agents hold considerable promise or potential risk. Thus, these compounds must undergo further rigorous study to determine the actual clinical efficacy and adverse effects before definitive therapeutic care recommendations can be offered. |
| | |
Authors:
|
Paolo S Silva; Jerry D Cavallerano; Jennifer K Sun; Lloyd M Aiello; Lloyd Paul Aiello |
Related Documents
:
|
7095333 - Metabolic control and serum hormone levels in relation to retinopathy in diabetic pregn... 11194933 - Serum concentrations of advanced glycation endproducts are associated with the developm... 22338103 - Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients t... |
Publication Detail:
|
Type: Evaluation Studies; Journal Article; Review Date: 2010-07-27 |
Journal Detail:
|
Title: Nature reviews. Endocrinology Volume: 6 ISSN: 1759-5037 ISO Abbreviation: Nat Rev Endocrinol Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-19 Completed Date: 2010-12-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101500078 Medline TA: Nat Rev Endocrinol Country: England |
Other Details:
|
Languages: eng Pagination: 494-508 Citation Subset: IM |
Affiliation:
|
Beetham Eye Institute, Joslin Diabetes Center, Department of Ophthalmology, Harvard Medical School, 1 Joslin Place, Boston, MA 02215, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Age of Onset Angiotensin-Converting Enzyme Inhibitors / adverse effects, blood, therapeutic use Antihypertensive Agents / adverse effects, blood, therapeutic use Blood Glucose / drug effects Diabetes Complications / blood, drug therapy Diabetic Retinopathy / blood, drug therapy, epidemiology*, etiology* Disease Progression Humans Hypoglycemic Agents / adverse effects, pharmacology, therapeutic use Models, Biological Polypharmacy* |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Blood Glucose; 0/Hypoglycemic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The growth hormone receptor: mechanism of activation and clinical implications.
Next Document: Grapefruit Juice Greatly Reduces the Plasma Concentrations of the OATP2B1 and CYP3A4 Substrate Alisk...